Explore News By Topic
04/04/2024
Prostate cancer cases expected to double worldwide between 2020 and 2040, new analysis suggests
Annual prostate cancer cases are projected to rise from 1.4 million in 2020 to 2.9 million in 2040, and annual deaths to increase by 85% to almost 700,000 over the same timeframe, mainly among men in low-and middle-income countries (LMICs). The Lancet Commission on prostate cancer argues that the ‘informed... Read More
03/23/2024
Atlanta Hawks Foundation and Ressler Gertz Family Foundation Team Up To Donate $150,000 to Prostate Cancer Foundation
**To download photos and video from the PCF check presentation, click here.** FOR IMMEDIATE RELEASE: 3/23/24 CONTACT: Max Strauss, Atlanta Hawks Brand Communications, [email protected] ATLANTA HAWKS FOUNDATION AND RESSLER GERTZ FAMILY FOUNDATION TEAM UP TO DONATE $150,000 TO PROSTATE CANCER FOUNDATION Nearly a Million Dollars Raised Since 2019... Read More
03/14/2024
The Prostate Cancer Foundation Announces 2023 Challenge Awards Totaling More Than $21 Million For Prostate Cancer Research
LOS ANGELES, Calif., March 14, 2024 – The Prostate Cancer Foundation (PCF) today announced the 2023 Class of PCF Team Challenge Award recipients and a total of more than $21 million in funding for innovative prostate cancer research. PCF Challenge Awards fund international, multi-institutional, cross-disciplinary teams of investigators conducting highly... Read More
03/05/2024
UroToday and PRIMR Announce Strategic Partnership to Enhance Clinical Trial Awareness
Digital Science Press / UroToday RENO, Nev., March 5, 2024 /PRNewswire/ -- UroToday, the premier global hub for urology news and education, and PRIMR, a pioneering oncology clinical trial patient education company, proudly announce their inaugural strategic partnership. This groundbreaking collaboration is set to redefine clinical trial awareness and education, marking a... Read More
02/22/2024
The Prostate Cancer Foundation and the American Cancer Society Announce First ACS-PCF Young Investigator Award
LOS ANGELES, Calif., February 22, 2024 – The Prostate Cancer Foundation (PCF) and the American Cancer Society (ACS) today announced the ACS-PCF Young Investigator Award totaling $225,000 over three years to support a novel health equity research project that aims to reduce disparities in access to modern prostate cancer care... Read More
01/11/2024
New Prostate Cancer Foundation-Funded Research To Speed Up Prostate Cancer Clinical Trials Worldwide
LOS ANGELES, Calif., January 11, 2024 -- New analysis of data published by Susan Halabi, PhD, of Duke University, USA could facilitate approval of new prostate cancer treatments almost two years earlier than the current standard. The study published online January 5, 2024, in the Journal of Clinical Oncology, reviewed... Read More
12/05/2023
The Prostate Cancer Foundation and Bayer Announce First Ever Bayer-PCF Health Equity Research Challenge Awards
LOS ANGELES, Calif., November 30, 2023 – The Prostate Cancer Foundation (PCF) and Bayer today announced three 2023 Bayer-PCF Health Equity Research Challenge Awards totaling $600,000. The awards will support novel health equity research projects with the goal of reducing racial and ethnic disparities in the diagnosis and treatment of... Read More
11/17/2023
Pfizer and Astellas’ XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy* in nonmetastatic castration-sensitive prostate cancer TOKYO and NEW YORK, November 16, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Pfizer Inc. (NYSE: PFE) today... Read More
10/25/2023
The Prostate Cancer Foundation and Bayer Announce First Ever Bayer-PCF Darolutamide Challenge Awards
LOS ANGELES, Calif., October 25, 2023 – The Prostate Cancer Foundation (PCF) and Bayer today announced two 2023 Bayer-PCF Darolutamide Challenge Awards totaling $2 million to support clinical investigations on darolutamide in prostate cancer. In 2019, the U.S. Food and Drug Administration approved Bayer’s Nubeqa® (darolutamide), an androgen receptor inhibitor... Read More
10/24/2023
The Prostate Cancer Foundation Announces The 2023 Young Investigator Awards Totaling More Than $6 Million for Prostate Cancer Research
LOS ANGELES, Calif., October 24, 2023 – The Prostate Cancer Foundation (PCF) today announced the Class of 2023 Young Investigator Award recipients totaling $6.1 million in funding for innovative prostate cancer research. PCF Young Investigator Awards are intended to identify a cohort of future research leaders who will keep the... Read More